Effect of LCZ696 on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With Hypertension

Hypertension Clinical Trial

Official title:

Effect of Sacubitril/Valsartan on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With Hypertension

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04800081
• Other study ID #: 2020A-247
• Status: Recruiting
• Phase: N/A
• Start date: July 9, 2020
• Est. completion date: July 9, 2021

Study information

• Verified date: March 2021
• Source: LanZhou University
• Contact: Ying Pei, MD
• Phone: +86-0931-17318717573
• Email: peiy19[@]lzu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To explore the efficacy of Sacubitril/Valsartan in the treatment of perimenopausal hypertensive patients, as well as the difference between the antihypertensive efficacy and valsartan, the therapeutic effect of its exposure to different factors and the protection of target organs.To provide reference for the clinical treatment of perimenopausal hypertension patients with shakubactrivalsartan.

1. To evaluate the effects of Sacubitril/Valsartan on urinary microalbumin and pulse wave velocity in perimenopausal hypertension patients.

2. To evaluate the clinical application of Sacubitril/Valsartan in the treatment of perimenopausal hypertension, so as to improve the blood pressure management ability and control rate of patients with such hypertension.

Description:

A total of 264 cases of perimenopausal patients with essential hypertension who were admitted to Department of Cardiology, Second Hospital of Lanzhou University,from January, 2020 to March,2021 will be enrolled and randomized to receive once-daily treatment with 100-400 mg of Sacubitril/Valsartan or 80-320 mg of Valsartan.The general information, menstrual history, cardiac ultrasound, urinal-renal function, PWV, baseline blood pressure, post-medication blood pressure, whether to use antihypertensive drugs and the type of antihypertensive drugs of the patients were enrolled.After 12 weeks of drug intervention, left ventricular mass indexwere measured by cardiac ultrasound, PWV, urinary microalbinin, 24-hour ambulatory blood pressure monitoring, biochemical indicators will be collected.SPSS22.0 statistical software was used for statistical analysis of PWV, urinary microalbumin, blood pressure and other results by paired data t-test, and the chi-square test was used for non-count data.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 264
• Est. completion date: July 9, 2021
• Est. primary completion date: June 9, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 40 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Patients with essential hypertension(SBP>140 and <180 mmHg, and/or DBP>90 and <110 mmHg))were diagnosed according to the hypertension diagnostic criteria of the Chinese Guidelines for Hypertension (2018 Revised Edition);

2. Female aged 45-55 years old and meeting the perimenopausal criteria in the STRAE+10;

3. No other complications, no treatment or ongoing antihypertensive therapy (SBP =140mmHg or Diastolic BP =90mmHg);

4. Agree to participate in the study and sign the informed consent;

Exclusion Criteria:

1. Secondary hypertension;

2. History of angioedema;

3. Heart failure NYHA grade III or above (excluding grade III);

4. Liver and kidney dysfunction (ALT or AST= three times the upper limit of normal value, that is, ALT=120U/L,AST=120U/L, creatinine clearance < 30ml/min);

5. Hyperkalemia (serum potassium =5.5mmol/L);

6. Moderate or above anemia (HGB=90g/L);

7. Bilateral renal artery stenosis;

8. History of stroke;

Related Conditions & MeSH terms

• Hypertension

Intervention

Drug:
• Sacubitril/Valsartan
Patients will be randomized to receive once-daily treatment with 100-400 mg of Sacubitril/Valsartan.
• Valsartan
Patients will be randomized to receive once-daily treatment with 80-320 mg of Valsartan.

Locations

Country	Name	City	State
China	Department of Cardiology, Second Hospital of Lanzhou University	Lanzhou	GuSu

Sponsors (1)

Lead Sponsor	Collaborator
LanZhou University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood pressure,24 hour automatic blood pressure monitoring,home blood pressure monitoring,Office blood pressure	Changes in this major indicators were detected before and after drug treatment in both groups	Evaluation at 12 weeks of treatment will be reported
Primary	urinary microalbuminuria	Changes in this major indicators were detected before and after drug treatment in both groups	Evaluation at 12 weeks of treatment will be reported
Primary	pulse wave velocity	Changes in this major indicators were detected before and after drug treatment in both groups	Evaluation at 12 weeks of treatment will be reported
Primary	ventricular mass indexwere measured by cardiac ultrasound	Changes in this major indicators were detected before and after drug treatment in both groups	Evaluation at 12 weeks of treatment will be reported
Secondary	Adverse events	such as arrhythmology,dizzy, headache,edema,cough.Other incidents are even more serious	During the drug intervention up to 30 days,60 days and 80days,it will bereported in the final.